The Central Nervous System (CNS) Disorders Market - Outlook to 2012.LYON, France -- Reportlinker.com announces that a new market research report related to the worldwide pharmaceutical industry is available in its catalogue. The CNS See Continuous net settlement. CNS See continuous net settlement (CNS). Market Outlook to 2012 To order that report: www.reportlinker.com/p061663/PRBW-CNS-Market.html For more information, contact Nicolas by email nbo@reportlinker.com , or by phone +33 4 37 65 17 03. Description CNS disorders constitute one of the most significant components of healthcare spending in the developed world, contributing to an estimated 35% of the disease burden within the seven major pharma markets. However, an increased presence of generic products and lack of innovative product launches have prompted a slowdown in market growth, which pharma and biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. companies are addressing through a shift in R&D focus towards disease areas with relatively low levels of innovation, such as Alzheimer's and Parkinson's disease Parkinson's disease or Parkinsonism, degenerative brain disorder first described by the English surgeon James Parkinson in 1817. When there is no known cause, the disease usually appears after age 40 and is referred to as Parkinson's disease. . This new report provides a detailed epidemiological analysis of major indications within the CNS disorders market, and examines the factors impacting their prevalence. The current opportunities and threats facing the market are assessed and the most promising potential growth areas across all indications are highlighted. The report also profiles the key trends influencing treatment sales and analyses the competitive dynamics of leading brands within each indication. Discover the key trends and growth drivers within the CNS market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this new report... Table of content Executive Summary Patient potential Global market analysis Pipeline analysis Competitive landscape Chapter 1 Epidemiology of CNS disorders Summary Introduction Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Major depressive disorder Major depressive disorder A mood disorder characterized by profound feelings of sadness or despair. Mentioned in: Conduct Disorder major depressive disorder (MDD MDD Major depressive disorder, see there ) Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Schizophrenia Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Migraine migraine (mī`grān), headache characterized by recurrent attacks of severe pain, usually on one side of the head. It may be preceded by flashes or spots before the eyes or a ringing in the ears, and accompanied by double vision, nausea, Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Epilepsy epilepsy, a chronic disorder of cerebral function characterized by periodic convulsive seizures. There are many conditions that have epileptic seizures. Sudden discharge of excess electrical activity, which can be either generalized (involving many areas of cells in Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Parkinson's disease Overview Diagnosis, treatment and management Epidemiology Forecast epidemiology Chapter 2 Global market analysis Summary Introduction Market analysis by country Licensing/generics trends Market analysis by indication Leading brands dynamics Key events in the CNS disorders market Revised suicidal warning labeling for SSRI SSRI selective serotonin reuptake inhibitor. SSRI n. Selective serotonin reuptake inhibitor; a class of drugs that inhibit the reuptake of serotonin in the central nervous system, used to treat depression and other anti depressants Increased risk of bone fractures associated with the use of SSRIs Launch of Lyrica (pregabalin) as a replacement product for Pfizer's Neurontin (gabapentin) US FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. calls for voluntary withdrawal of all pergolide-based products Launch for first transdermal patch transdermal patch: see skin patch. formulation of Novartis' Exelon for the treatment of AD Arrival of generic competition to key products in the CNS market in 2005-6 Depression Market analysis by drug class Competitive dynamics of anti-depressants Leading brands in the Anti-depressants market Selective Serotonin Reuptake Inhibitors Selective Serotonin Reuptake Inhibitors Definition Selective serotonin reuptake inhibitors are medicines that relieve symptoms of depression. Purpose (SSRIs) Market dynamics Key brands analysis Selective Norepinephrine Reuptake Inhibitors Norepinephrine reuptake inhibitors (NRIs), also known as noradrenaline reuptake inhibitors (NARIs), are compounds that elevate the extracellular level of the neurotransmitter norepinephrine in the central nervous system by inhibiting its reuptake from the (SNRIs) Key brands analysis Others Anti-depressants sales forecasts Sales forecast A key input to a firm's financial planning process. External sales forecasts are based on historical experience, statistical analysis, and consideration of various macroeconomic factors. to 2012 Alzheimer's disease Market analysis by drug class Competitive dynamics of subclasses of anti-Alzheimer's disease Leading brands in the Anti-Alzheimer's market Cholinesterase inhibitors cholinesterase inhibitor n. A drug, such as neostigmine, that restores myoneural function by inhibiting the biodegradation of acetylcholine. Also called acetylcholinesterase inhibitor. market analysis Market dynamics Key brands analysis NMDA receptor antagonists NMDA receptor antagonists are a class of anesthetics that work to antagonize, or inhibit the action of, the N-methyl d-aspartate receptor (NMDAR). They are used as anesthesia for animals and, less commonly, for humans; the state of anesthesia they induce is referred to as Market dynamics Key brands analysis Anti-Alzheimer's drugs sales forecasts to 2012 Epilepsy Market analysis by drug class Competitive dynamics of subclasses of anti-epileptics Leading brands in the anti-epileptic market Traditional anti-epileptics Market dynamics Key brands analysis Second generation anti-epileptics market analysis Market dynamics Key brands analysis Anti-epiletics sales forecasts to 2012 Migraine Market analysis by drug class Leading brands of anti migraine drugs Triptans Key brands analysis Anti-migraine sales forecasts to 2012 Parkinson's disease Market analysis Leading brands in the anti Parkinson's market Table 2.30 summarizes the performance of the leading anti-Parkinson's disease brands in 2005-6 COMT inhibitors COMT inhibitors Drugs that block catechol-o-methyl transferase, an enzyme that breaks down dopamine. COMT inhibitors include entacapone and tolcapone. Mentioned in: Parkinson Disease Key brands analysis Dopaminergics Key brands analysis Dopamine Agonists A dopamine agonist is a compound that activates dopamine receptors, mimicking the effect of the neurotransmitter dopamine. Uses Some medical drugs act as dopamine agonists; they are typically used for treating Parkinson's disease, and may be useful for restless legs Key brands analysis Anti-Parkinson's drugs sales forecasts to 2012 Schizophrenia Market analysis Leading brands in the Schizophrenia market Typical anti-psychotics Atypical antipsychotics The atypical anti-psychotics (also known as second generation anti-psychotics) are a class of prescription medications used to treat psychiatric conditions. Some atypical anti-psychotics are FDA approved for use in the treatment of schizophrenia. Key brands analysis Schizophrenia drugs sales forecasts to 2012 Total CNS disorders' sales forecasts to 2012 Chapter 3 Pipeline analysis Summary Introduction Key trends in R&D New class of drugs Dual mechanism of action Combination drugs New drug delivery formulations The CNS disorders pipeline Leading drugs in development Profiles of key pipeline products Phase II compounds Ketasyn/AC-1202 PBT PBT Provider Backbone Transport (networking technology adding determinism to ethernet) PBT Polybutylene Terephthalate PBT Profit Before Tax PBT Paper Based Test (education) 2 (Metal Protein Attenuating Compound) Phase III Noun 1. phase III - a large clinical trial of a treatment or drug that in phase I and phase II has been shown to be efficacious with tolerable side effects; after successful conclusion of these clinical trials it will receive formal approval from the FDA compounds vilazodone ACP (Associate Computing Professional) The award for successful completion of an examination in computers offered by the ICCP. It is geared to newcomers in the computing field. For more information, visit www.iccp.org. ACP - Algebra of Communicating Processes 103 (pimavanserin) MK-0974 safinamide Drugs in registration DVS-233 (desvenlafaxine) Trexima (sumatriptan/naproxen) Vimpat (lacosamide) Recently marketed drugs Invega (paliperidone) Neupro (rotigotine transdermal patch) Inovelon (rufinamide) Pipeline forecasts CNS disorders pipeline forecasts Chapter 4 Competitive landscape Summary Introduction Company market shares Johnson & Johnson Overview Sales focus by indication Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Sales and Promotion analysis Drivers of growth Resistors of growth Glaxo SmithKline Overview Sales focus by indication Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Sales and Promotion analysis Drivers of growth Resistors of growth Pfizer Overview Sales focus by indication Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Sales and Promotion analysis Drivers of growth Resistors of growth Lilly Overview Sales focus by indication Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Sales and Promotion analysis Drivers of growth Resistors of growth Sanofi Aventis Overview Sales focus by indication Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Sales and Promotion analysis Drivers of growth Resistors of growth Novartis Overview Sales focus by indication Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Sales and Promotion analysis Drivers of growth Resistors of growth AstraZeneca Overview Sales focus by indication Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Sales and Promotion analysis Drivers of growth Resistors of growth Wyeth Overview Sales focus by indication Marketed product portfolio R&D pipeline analysis Strategic and growth analysis Sales and Promotion analysis Drivers of growth Resistors of growth Forest Labs Overview Sales focus by indication Marketed product portfolio R&D pipeline analysis Sales and Promotion analysis Drivers of growth Resistors of growth Chapter 5 Appendix IMS (1) See IP Multimedia Subsystem. (2) (Information Management System) An early IBM hierarchical DBMS for IBM mainframes. IMS was widely implemented throughout the 1970s under MVS and continues to be used under z/OS. data N1 Anaesthetics - Includes Anaesthetics local, others N2 Analgesics Analgesics Definition Analgesics are medicines that relieve pain. Purpose Analgesics are those drugs that mainly provide pain relief. Index More market research reports? Go to http://www.reportlinker.com http://market-research.typepad.com/agricultural_chemicals/ |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion